ATE480254T1 - Hip/pap polypeptide zusammensetzung zur verwendung zur leberregeneration und zur vorbeugung von leberinsuffizienz - Google Patents

Hip/pap polypeptide zusammensetzung zur verwendung zur leberregeneration und zur vorbeugung von leberinsuffizienz

Info

Publication number
ATE480254T1
ATE480254T1 AT04740077T AT04740077T ATE480254T1 AT E480254 T1 ATE480254 T1 AT E480254T1 AT 04740077 T AT04740077 T AT 04740077T AT 04740077 T AT04740077 T AT 04740077T AT E480254 T1 ATE480254 T1 AT E480254T1
Authority
AT
Austria
Prior art keywords
amino acid
hip
liver
pap
polypeptide composition
Prior art date
Application number
AT04740077T
Other languages
English (en)
Inventor
Laurence Christa
Christian Brechot
Marie-Therese Simon-Gage-Soufflot
Alain Pauloin
J Guilherme Tralhao
Original Assignee
Inst Nat Sante Rech Med
Univ Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Rene Descartes filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE480254T1 publication Critical patent/ATE480254T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04740077T 2003-06-18 2004-06-18 Hip/pap polypeptide zusammensetzung zur verwendung zur leberregeneration und zur vorbeugung von leberinsuffizienz ATE480254T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03291487A EP1488798A1 (de) 2003-06-18 2003-06-18 HIP/PAP polypeptide Zusammensetzung zur Verwendung zur Leberregeneration und zur Vorbeugung von Leberinsuffizienz
PCT/EP2004/006633 WO2004112824A1 (en) 2003-06-18 2004-06-18 Hip/pap polypeptide composition for use in liver regeneration and for the prevention of liver failure

Publications (1)

Publication Number Publication Date
ATE480254T1 true ATE480254T1 (de) 2010-09-15

Family

ID=33396036

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740077T ATE480254T1 (de) 2003-06-18 2004-06-18 Hip/pap polypeptide zusammensetzung zur verwendung zur leberregeneration und zur vorbeugung von leberinsuffizienz

Country Status (15)

Country Link
US (2) US20060276388A1 (de)
EP (2) EP1488798A1 (de)
JP (1) JP4709141B2 (de)
CN (1) CN1835764B (de)
AT (1) ATE480254T1 (de)
AU (1) AU2004248914B2 (de)
CA (1) CA2529896C (de)
CY (1) CY1110941T1 (de)
DE (1) DE602004029038D1 (de)
DK (1) DK1638594T3 (de)
ES (1) ES2351893T3 (de)
PL (1) PL1638594T3 (de)
PT (1) PT1638594E (de)
SI (1) SI1638594T1 (de)
WO (1) WO2004112824A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1488798A1 (de) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide Zusammensetzung zur Verwendung zur Leberregeneration und zur Vorbeugung von Leberinsuffizienz
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
EP1900749A1 (de) 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen
US7923014B2 (en) * 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
EP2260857A1 (de) * 2009-06-11 2010-12-15 Alfact Innovation Neuartige Anwendungen von HIP/PAP und Derivate davon
WO2011003098A1 (en) * 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
EP2508607A1 (de) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medikament zur Leberregeneration und zur Behandlung von Leberversagen
EP2687225A1 (de) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP-Protein und Derivate davon zur Verwendung bei der Behandlung von Krebs
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US8893292B2 (en) 2012-11-14 2014-11-18 Mitsubishi Electric Research Laboratories, Inc. Privacy preserving statistical analysis for distributed databases
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
RU2559935C1 (ru) * 2014-06-10 2015-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ стимуляции регенерации резецированной печени l-аргинином
RU2590859C1 (ru) * 2015-06-30 2016-07-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Способ дистантной стимуляции регенерации гепатоцитов
RU2601160C1 (ru) * 2015-07-09 2016-10-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОмГМУ Минздрава России) Способ резекции печени у мелких лабораторных животных
ES2983978T3 (es) * 2016-01-08 2024-10-28 Univ Kyoto Medicina que comprende ADAMTS13 como ingrediente principal
RU2636194C1 (ru) * 2016-11-23 2017-11-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ стимуляции репаративной регенерации печени после ее резекции
CN107936111B (zh) * 2017-12-16 2021-09-07 广州安辰新药研究院有限公司 一种hip/pap蛋白的制备方法
CN114702550B (zh) * 2018-09-18 2023-09-12 广州领晟医疗科技有限公司 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途
CN110669126B (zh) * 2019-10-23 2022-08-16 广州领晟医疗科技有限公司 多肽gpr5及其促进肝细胞增殖和抑制肝细胞凋亡的用途
CN110627866B (zh) * 2019-10-23 2022-10-18 广州领晟医疗科技有限公司 多肽rly4及其促进肝再生和抑制肝细胞凋亡的用途
EP4262976A1 (de) * 2020-12-21 2023-10-25 Flagship Pioneering Innovations V, Inc. Verwendung von zellturn-faktoren zur erhöhung der geweberegeneration
EP4085922A1 (de) 2021-05-07 2022-11-09 The Healthy Aging Company Hip/pap-protein oder ein derivat davon zur behandlung von mononeuropathia multiplex
CN113528639B (zh) * 2021-06-04 2023-06-13 南方医科大学南方医院 一组预测慢加急性肝功能衰竭预后的标志物及其应用
EP4252766A1 (de) 2022-04-01 2023-10-04 The Healthy Aging Company Hip/pap-protein oder derivat davon zur behandlung und/oder vorbeugung einer durch einen hohen cxcl5-serumspiegel in einem individuum gekennzeichneten störung
CN114887036B (zh) * 2022-05-12 2026-02-10 中南大学湘雅二医院 抗菌肽在制备对乙酰氨基酚诱导的急性肝损伤和/或肝衰竭治疗制剂中的应用
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
CN116004825B (zh) * 2022-12-08 2024-12-31 上海交通大学医学院附属上海儿童医学中心 Reg3a在制备辅助诊断或治疗肝母细胞瘤的试剂或药物中的应用
EP4464330A1 (de) 2023-05-17 2024-11-20 The Healthy Aging Company Hip/pap-protein oder derivat davon zur behandlung einer kognitiven störung im zusammenhang mit angststörungen
WO2024236159A1 (en) 2023-05-17 2024-11-21 The Healthy Aging Company Hip/pap protein or a derivative thereof for treating a cognitive disorder associated with anxiety disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661187B1 (fr) * 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
FR2700011B1 (fr) * 1992-12-24 1995-02-24 Inst Nat Sante Rech Med Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.
EP1488798A1 (de) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide Zusammensetzung zur Verwendung zur Leberregeneration und zur Vorbeugung von Leberinsuffizienz

Also Published As

Publication number Publication date
US20110144036A1 (en) 2011-06-16
PT1638594E (pt) 2010-12-03
JP2006527733A (ja) 2006-12-07
EP1638594A1 (de) 2006-03-29
ES2351893T3 (es) 2011-02-11
JP4709141B2 (ja) 2011-06-22
CN1835764A (zh) 2006-09-20
PL1638594T3 (pl) 2011-08-31
DE602004029038D1 (de) 2010-10-21
SI1638594T1 (sl) 2011-03-31
CY1110941T1 (el) 2015-06-10
EP1638594B1 (de) 2010-09-08
US20060276388A1 (en) 2006-12-07
DK1638594T3 (da) 2010-12-20
CA2529896A1 (en) 2004-12-29
AU2004248914B2 (en) 2010-02-25
WO2004112824A1 (en) 2004-12-29
AU2004248914A1 (en) 2004-12-29
CN1835764B (zh) 2014-07-09
US8329661B2 (en) 2012-12-11
CA2529896C (en) 2014-02-11
EP1488798A1 (de) 2004-12-22

Similar Documents

Publication Publication Date Title
ATE480254T1 (de) Hip/pap polypeptide zusammensetzung zur verwendung zur leberregeneration und zur vorbeugung von leberinsuffizienz
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
ATE538805T1 (de) Fgf-varianten und anwendungsverfahren dafür
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
DK1668031T3 (da) Homogene præparater af IL-29
ATE173478T1 (de) Varianten des pankreatischen rinder- trypsininhibitors, deren herstellung und verwendung
ATE291616T1 (de) Neue carbonyl-reduktase, gen davon und verfahren der anwendung derselben
ATE383424T1 (de) Polypeptide, deren herstellung und verwendung
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
DE60125751D1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DK1501936T3 (da) Familie af cytokin-proteiner
PL1712223T3 (pl) Preparat farmaceutyczny rekombinowanego czynnika VIII zliofilizowany bez albuminy jako stabilizatora
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DE60326723D1 (de) Verwendung von zusammensetzungen mit der biologischen aktivität der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
PT2289533E (pt) Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
ATE356205T1 (de) Milcherzeugungsassoziiertes immunotropisches rinderprotein (cd14), kodierendes gen und verwendung zur aktivierung von b-zellen
ATE353669T1 (de) Allergievakzine sowie ihre herstellung
WO2021107473A1 (ko) 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
DE50211988D1 (de) Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren
JP2003522131A5 (de)
SE9402332D0 (sv) Igf-1
DE60231913D1 (de) Mit fettzellendifferenzierung assoziiertes gen und protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1638594

Country of ref document: EP